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Relationship of H-ras1, L-myc, and p53
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and Prognosis
byAinsley Weston,1 Neil E. Caporaso,2 Laurie S.
Perrin,1 Haruhiko Sugimura,3 Seiichi Tamai,4 Theodore
G. Krontiris,5 Benjamin F. Trump,6 Robert N. Hoover,1
and Curtis C. Harris1
Proto-oncogenes (H-ras-1 and L-myc) and tumor-suppressor gene (p53) loci have been implicated in lung
carcinogenesis. DNA restriction fragment length polymorphisms at these gene loci are being evaluated in a
case-control study as markers predictive ofrisk for cancer orofprognosis when cancer is present. The cases
and controls had a cigarette-smoking history of40 or more pack years or other abnormalities in pulmonary
function tests, their ages were closely matched (64 years for cases and 61 years for controls) and the ratio of
Caucasians to African Americans was close to unity (cases, 0.95:100, controls, 1.00:0.88). The H-ras-1 gene
contains an insertion deletion polymorphism. Inheritance ofrare H-ras-1 alleles, defined byMspI digestion,
confers arelative risk forlungcancerof2.0 (95% confidence interval, 0.5-7.3) forCaucasians and 3.2 (0.9-11.6)
for African Americans (74 cases, 67 controls). The L-myc gene sequence has a restriction site (EcoRl)
polymorphism betweenthesecondandthirdexons. Inheritance ofrestriction site-presentalleleswasreported
to confer poor prognosis (presence of lymph node metastases) in Japanese lung cancer patients. This
hypothesis wastested inbothcase-control studysubjects (56 cases, 55 controls) and additional surgical cases
(40), but no evidence was found to support the hypothesis in the U.S. population. Thep53 gene is a tumor-
suppressorgenethatcanencodeeitheraproline oranarginine inthe 72ndresidue.Noassociations was found
between the minor allele (proline) and diagnosis of lung cancer (76 cases, 68 controls). Importantly, the
observed allelic distributions at each of these genetic loci (H-ras-1, L-myc, and p53) were found to be
significantly different between African Americans and Caucasians in a U.S. population.
Introduction
Epidemiological andpharmacogenetic studieshave pos-
tulated the existence of inherited predisposition for lung
cancer (1,2). Furthermore, familial studies suggest a
genetic component to this disease, in spite ofits nowwell
documented environmentaletiology[tobacco smoking(3)].
Few useful genetic markers exist, however, that allow
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assessment of individual risk for of human lung cancer.
The biomarkers evaluated in the current study consist of
proto-oncogenes and tumor-suppressor genes that are
implicated in the genesis human lung cancer: H-ras-1 (4),
L-myc(5),andp53(6).Agrowingnumberofinvestigations
by others have attempted to evaluate various potential
biomarkers of individual cancer risk, but most of these
sufferfrominadequate studydesign.Withrespecttolung
cancer, case-control studies are oflimitedvalue ifage and
tobacco smoking history are not controlled. The studies
reported here were undertaken in the context ofa formal
case-control design that accounts for age, tobacco smok-
ing history, gender, ethnic background, occupational his-
tory, and familial history ofcancer.
Materials and Methods
Accrual ofStudy Subjects
The design ofthis epidemiological case-control studyof
lung cancer is described in detail elsewhere (7). Briefly,WESTON ET AL.
patients with histologically confirmed lung cancer who
hadnotreceivedradiation orchemotherapywererecruited
at the University of Maryland and Baltimore Veterans
Administration Hospitals between 1985 and 1989. Histo-
logical diagnosis oflung cancer was confirmed by patho-
logical review. Two control groups were recruited: chronic
obstructive pulmonary disease (COPD) patients and
patients with cancers at anatomical sites other than the
lung and bladder. The COPD patients all had a clinical
diagnosis and demonstrated abnormalities in pulmonary
function tests (forcedexpiratoryvolumein 1 sec [FEV1] of
less than 75% predicted normal and/or FEV1/forced vital
capacitylessthan 75%predicted) and/oracigarette smok-
ing history of40 pack-years or more. The second control
group was recruited from among cancer patients with a
variety of malignancies including cancers of the colon,
esophagus, stomach, and breast and melanoma.
Studyrecruitswere screenedforeligibilityorexclusion.
Exclusion criteriaincluded: treatmentin anintensive care
unit,bloodpressure < 100/60mmHg,inabilitytotakeoral
medication ortobeinterviewed, general anesthesiawithin
the last 5 days, severe renal or liver disease (creatinine >
4.0 mg/mL or total bilirubin > 3 IU, or serum glutamic-
oxaloacetic transaminase or serum glutamic-pyruvic trans-
aminase > 300IU),previousdiagnosisofseparateprimary
malignancy other than basal-cell carcinoma, inability or
refusal to give informed consent, or physician refusal. An
interview was administered to eligible subjects by a
trained study nurse, and data were collected on socio-
demographic andanthropomorphic characteristics, recent
and remote tobacco use, personal medical history, usual
and recent diet, current medications, familial history of
cancer, alcohol use, and occupational and residential his-
tory. Medical recordswere also reviewed to abstract other
relevant information.
Southern Hybridization for Analysis ofthe
H-ras-1 Gene
High-molecular-weight DNAwassubjected todigestion
with MspI/HpaII. Primary diagnosis of H-ras-1 alleles
was made according to criteria previously described, fol-
lowing MspI digestion (8). Separation ofrestriction frag-
ments in the DNA digests by agarose gel (0.8-0.9%)
electrophoresis was achieved using constant voltage (40-
50V)for10-16hr, sothatthedyefrontmigrated adistance
ofatleast12cm. Standardsforthefourcommonalleles(al,
a2, a3, and a4) as well as standard restriction fragments
for the following allelic designations, al.1, al.2, al.3, a2.1,
a2.2, a2.3, and a3.5, were used to facilitate allelotyping.
Followingelectrophoresis, gels were treated with alkali
(400 mM NaOH; 600 mM NaCl; 25 min) and neutralized
(1.5 M NaCl; 500 mMTris-HCl; pH 7.5; 30 min), and DNA
was immobilized by capillary transfer onto nylon mem-
brane support matrices. Samples were hybridized to the
full-length, 6.6kb, 32P-labeled, human H-ras-1 BamHI-
fragmentunderstringentconditions (NaCl, 100mM;SDS,
0.5%; dextran sulfate, 10%; 65°C; 16 hr). The membranes
were washed under increasingly stringent conditions
(final conditions: 37.5 mM NaCl; 3.8 mM HOC [COONa]
[CH3COO*Na]2; 0.1% SDS; 65°C; 30min), andX-rayfilms
(Eastman Kodak Company, Rochester, NY) were used to
detecthybridization ofthe radioactive probe.Allelotyping
wasbased onthe original systemreported byKrontiris et
al. (9); in which common alleles are designated by an
integer (i.e., al, a2, a3, and a4), and other alleles are
designatedbydecimalswithrespecttothe closestsmaller
common allele (e.g., al.1, al.2 for alleles larger than al but
smallerthana2, anda2.1, a2.2foralleleslargerthana2but
smallerthana3).Similarly, al.25isdeterminedtobelarger
than al.2 but smaller than al.3. Authentic, well-charac-
terized alleles from original studies were frequently used
in the analysis oftest samples.
Polymerase Chain Reaction-Restriction
Enzyme Analysis for L-myc
Polymerase chain reaction-restriction enzyme (PCR-RE)
analysis for L-myc was carried out on 56 lung cancer
patients (clinical diagnosis), 36 COPD patients, and 19
other cancer patients who had been enrolled in the case-
control study. Since the allelic frequencies at the L-myc
locus were found to differ by race (African American
versus Caucasian), further samples were obtained (from
traumavictims; 16Caucasian and24AfricanAmerican) to
test the hypothesis of an association between race and
allelic frequency. Additional lung cancer cases were also
obtained at surgery (27 Caucasian and 23 African Ameri-
can) to address rigorously the question of an association
between the presence of metastatic disease and the dis-
tribution of L-myc alleles in lung cancer. Genomic DNA
was amplified using primers that flank the polymorphic
EcoRI site in the L-myc gene (5'AGTTCACTCACAGGC-
CACAT3'-* and +- 5'TGCATATCAGGAAGCTTGAG3').
The PCR was performed using a DNA thermal cycler
(Perkin-Elmer Cetus, Emeryville, CA), amplified DNA
segments were digested with EcoRI and subjected to
electrophoresisinpolyacrylamidegels(8%) (NewEngland
Biolabs, Beverly, MA). The gels were treated with an
ethidium bromide solution and examined underultraviolet
light. Arepresentative subset ofsamples was analyzed by
Southern hybridization with the 1.9-kb EcoRV/SmaI frag-
ment of an L-myc cDNA clone to corroborate the PCR-
RE analyses (10).
Polymerase Chain Reaction-Restriction
Enzyme Analysis forp53
AneasyPCR-RE genotypingtestwasdeveloped onthe
basis of previous reports (11,12). The method used here,
however, included an important modification: the primer
flanking codon 72 in the 5' region contained a singlebase-
pair mismatch (resulting in the formation of a new AccII
restrictionsitebetweenexon2andexon3;thatis,anAtoC
change at nucleotide position 11863 ofp53) to control for
completion ofdigestion. DNA samples were amplified for
35 cycles using a standard protocol (13) either with
primers 1 and A (below) or by a hemi-nested strategy
using primers 1 and A followed by a further 35 rounds
of amplification with primers 1 and B: primer 1 =
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FIGURE 1. Southern hybridization analyses that identified 13 of 23 H-ras-1 alleles in 141 subjects in an epidemiological study of lung cancer. The
allelomorphs were diagnosed according to previously defined criteria to be as follows: (blotA) a, al,a3; b, a2,a2; c, al,a4; d, al,a3.5; e, al,al;f, a2,a4; g,
a3.5,a4; h,al,al.2; i, al,al;j,al,a5.2; (blotB)k,a3.5,a4; 1,aO.l,aO.l; m,al.2,a3.5; n,al,a2,a3,a4 (standard); o,al,a3.5; p,a2,a2; (blotC) q,al,al.2; r,al,a2.3; s,
al.25,al.3; t, al,a2,a3,a4 (standard); u, aO.15,al; and v, a2.2,a3.3.
5'CCCCAACCCCAGCCCCCTAGCAGAGACCTGTGGG-
ACGCG3' -+ (mismatch position underlined), primer 2 =
5'TGTCATCTTCTGTCCCTTCCCAGA3' and primer
B = +- 5'ACACCGGCGGCCCCTGCACCA3'. The re-
sulting PCR products were digested to completion with
AccII and analyzed bypolyacrylamide gel electrophoresis
(12%in Tris-borate:EDTA[45mM:1 mM]bufferpH8.3).A
small, representative subset of samples was analyzed by
dideoxy-chain termination-DNA sequencing (14) to con-
firm the results ofthe PCR-RE analyses.
Statistical Analysis
Arithmetic means, standard errors, correlation coeffi-
cients, Student's t-test stepwise and linear regression
were performed using the SAS statistical package (15).
Results
Analysis ofthe H-ras-1 Polymorphism
Twenty-three discrete restriction fragments (MspI)
were found in 141 study subjects for the H-ras-1 proto-
oncogene. Resolution of13 ofthese restriction fragments
is shown in Figure 1, after hybridization with an H-ras-1
clone. Common, intermediate, and rare alleles were deter-
mined according to the criteria defined above. The allelic
distribution ofH-ras-1 MspI fragments was different for
African Americans and for Caucasians residing in the
United States. Notably, an allele designated a3.5, avariant
of the common a4 allele, was common among African
Americans. An excess of rare alleles was observed in lung
cancer patients compared to both COPD and nonpulmon-
ary cancer controls (Table 1). In Caucasians, rare alleles
were found to be approximately twice as frequent in lung
cancerpatients as in the COPD or nonlung cancer control
groups (x2 = 6.5, p < 0.05, degrees offreedom (df = 2);
the same comparison in African Americans showed a
3-fold excess of rare alleles in the cases (X2 = 26.4,
p < 0.0001, df = 2). Similarfindings weremadewhenlung
adenocarcinomas were excluded (X2 = 9.9, p < 0.01,
df = 2, for Caucasians; x2 = 25.9, p < 0.0001, df = 2, for
African Americans).
Since allelic frequency could differ by race (8), Cauca-
sians and African Americans were analyzed indepen-
dently for relative risk for lung cancer (Table 2). Although
small numbers in each group hamper the analysis, an
increase in the number of rare alleles for lung cancer
(excluding adenocarcinoma) was observed in African
Americans. Crude odds ratios for risk based on the num-
berofrare alleles showelevatedriskin allindividualswith
rare alleles and increasing risk based on the number of
rare alleles in the four comparisons considered: Cauca-
sians and African Americans, considering all lung cancer
cases and excluding cases with adenocarcinoma of the
lung. The trend is statistically significant only for non-
adenocarcinoma of the lung in African Americans (X2 =
Table 1. H-ras-1 allele frequencies in subjects with lung cancer and pooled controls.
Caucasians (n = 78) African Americans (n = 63)
Lung cancer Lung cancer
Adenocarcinoma Adenocarcinoma
All lung cancer excluded Pooled controlsb All lung cancer excluded Pooled controlsb
Allelotypea (n = 41) (n = 25) (n = 37) (n = 33) (n = 23) (n = 30)
Common 0.79 (65)c 0.74 (37) 0.82 (61) 0.41 (27) 0.39 (18) 0.68 (41)
Intermediate 0.07 (6) 0.08 (4) 0.11 (8) 0.36 (25) 0.35 (16) 0.23 (14)
Rare 0.13 (11) 0.18 (9) 0.07 (5) 0.21 (14) 0.26 (12) 0.08 (5)
aFrequencies ofcommon, intermediate, and rare alleles for Caucasian populations are given in Weston et al. (22).
bPooled controls are the sum of chronic obstructive lung disease patients (20 African American, 10 Caucasian) and nonlung cancer patients with
cancer (12 African American, 25 Caucasian).
cNumber ofalleles in parentheses.
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FIGURE 2. Southern blot analysis (A, B, C) and polymerase chain reaction (PCR) restriction fragmentlengthpolymorphism analysis (D, E, F) ofthe
L-myc proto-oncogene locus. Genomic DNA samples were digested with EcoRI, and immobilized DNA was hybridized to a human 1.9-kb L-myc
fragment (A, B, C). Three possible genotypes are shown; the L-L homozygote (A), the S-S homozygote (B) and the L-S heterozygote (C). Samples of
DNA that had been produced by the PCR using primers that flank the polymorphic restriction site were digested with EcoRI, electrophoresed in
polyacrylamide gels, and stainedwithethidiumbromide (D, E, F). Thesefigures (D, E, F) wereproducedbyphotographingthenegative oftheethidium
stained-fragment. The corresponding patterns for an L-L homozygote, an S-S homozygote, and an L-S heterozygote are shown in D, E, and FE
respectively.
3.9, df = 1, p = 0.05). Adjustment of these results for
other risk factors for lung cancer evaluated in this study,
for example smoking (pack years), age, family history of
lung cancerin first-degree relatives, and the debrisoquine
metabolic phenotype, revealed no important confounding
factors.
Analysis ofthe L-myc Polymorphism
Southern blotanalysis ofhuman genomic DNAsamples
that had been digested with EcoRI revealed a DNA
restriction fragment length polymorphism consisting of
two alleles at the L-myc locus (Fig. 2A-C). The PCR was
also used to reveal this polymorphism in genomic DNA
samples when primers that flank the EcoRI restriction
site wereusedtoamplify aDNAsegmentof267basepairs
(Fig. 2D-F). Initially, the twomethods were applied to the
same DNA samples, and it was found that the PCR and
Southern hybridization ofEcoRI-digested materials gave
consistent results (Fig. 2).
A highly significant difference in allelic distribution
between African Americans and Caucasians was found
(Table 3); the distributions for all subjects was consistent
with the Hardy-Weinberg equilibrium (16). The case-
control data show that in the Caucasian population the
ratioofrestriction site-absentalleles (L-alleles) torestric-
tionsite-present(S-alleles) was0.509:0.491,whereasinthe
African American population the distribution was
0.277:0.763. Similarly, among a group of trauma victims,
allele frequencies were 0.562:0.438 and 0.145:0.855 in Cau-
casians and African Americans, respectively.
In the lung cancer case-control study, PCR-RE or
Southern hybridization analyses for L-myc were con-
Table 2. Crude odds ratio for risk oflung cancer with H-ras-1 rare alleles in different racial groups.
Presence of Lung Pooled
rare allelesa cancer controls RRb 95% CIc X2 p
Caucasians (n = 78)
34 33 1.0
+ 8 4 2.0 0.5-7.3 1.1 0.29
Caucasians (n = 62)
(adenocarcinoma excluded)
19 33 1.0
+ 6 4 2.6 0.7-10.4 1.8 0.18
African Americans (n = 63)
22 26 1.0
+ 11 4 3.2 0.9-11.6 3.3 0.07
AfricanAmericans (n = 53)
(adenocarcinoma excluded)
14 26 1.0
+ 9 4 4.2 1.1-16.0 4.3 0.04
a(+) Indicates individuals with rare alleles, (-) indicates common or intermediate frequency alleles.
bRR = crude odds ratio (relative risk); RR ofthe subjects with no rare allele is 1.0.
CI= Cornfield 95% confidence interval.
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Table 3. Frequencies ofL-myc alleles in different ethnic groups.
Genotypea
Subjects L-L L-S S-S Total X2 p
In case-control study
Caucasians 13 32 12 57
11.6 0.0007
African Americans 6 18 30 54
Total 19 50 42 111
Trauma victims
Caucasians 4 10 2 16
15.0 0.0001
African Americans 0 7 17 24
Total 4 17 19 40
aDNArestrictionfragmentlength polymorphism(RFLP) pattern determined bySouthernblotorpolymerase chainreaction-RFLPanalysis, L = 10
kb and S = 6.6 kb EcoRI fragments ofthe L-myc proto-oncogene.
ducted on a total of 111 subjects; the allelic distributions are
given in Table 4. When race and other variables were not
controlled for, there was no association between allelic fre-
quency and lung cancer (likelihood ratio x2 = 1.14,
p = 0.56, df = 2). In addition, the allelic frequencies were
similar in each group (likelihood ratio x2 = 0.12, p = 0.94,
df = 2, n = 55). When a variety of other study variables
were entered into a multivariate statistical model to predict
lung cancer, neither race nor the number ofrestriction site-
present alleles was found to be associated with cancer
diagnosis. The effect of a number ofstudy variables on the
number ofalleles was also testedusing amultivariate linear
regression model: neither lung cancer diagnosis nor any
otherstudycharacteristic testedpredicted the presence ofa
specific allelotype, with the exception of race (F = 12.79,
p = 0.0005). Thus, African Americans are more likely to
have restriction site-present alleles than Caucasians. The
distribution ofL-myc alleles was alsounrelated tohistologic
subtype oflung cancer (data not shown).
There does not appear to be any relationship between
clinical stage of lung cancer and L-myc alleles in either
African Americans or Caucasians. Similarly, within a group
ofsurgically diagnosed Caucasian lung cancerpatientswith
orwithoutlymphnodemetastasis, noassociationwith L-myc
genotype was observed. In these latter studies, the number
of Caucasian patients was sufficiently large to make valid
statistical analyses however, the number ofAfrican Ameri-
can patients was too small to evaluate the relationship
between lymph node metastasis and the L-myc genotype.
Analysis ofp53 Polymorphism
Figure 3 shows the strategy for PCR-RE analysis of
exon4 ofp53. Dideoxy-chain termination DNAsequencing
of the PCR products was performed to confirm their
authenticity (DNAsequencing analysis was performed on
a small subset of samples only). PCR analysis with
restriction enzyme digestion was performed on 144 study
subjects (76 cases and 68 controls). There was no associa-
tion between presence ofthe p53 genotype and diagnosis
of lung cancer (small-cell and nonsmall-cell combined);
however, the observed allelicdistribution was significantly
different between African Americans and Caucasians
(X2 = 20.8, p< 0.0001, df = 2).
Discussion
Molecular epidemiological studies ofpotential lung can-
cerriskfactors havebeen described.Acase-control study
formathas been used to evaluate the relationship between
risk of developing lung cancer, or prognosis (when lung
cancer is present), and genotype at the H-ras-1, L-myc,
and p53 gene loci. The results ofthese studies show that
individuals with H-ras-1 rare alleles are at increased risk
forlung cancer(especiallyfornonadenocarcinoma inAfri-
canAmericans); thatthe L-myc genotype is notindicative
oflung cancerrisk ordisease outcome in a U.S. population
(prognosis, as measured by performance status, tumor
stage, or presence oflymphnodemetastasis); andthatthe
Table 4. Allelic distribution ofL-myc in a case-control study oflung cancer.
Genotypea
Subjects L-L L-S S-S Total 2b p
Lung cancer cases 9 28 19 56
All controls 10 22 23 55 1.14 0.56
Total 19 50 42 111
Controls with cancer at sites 3 8 8 19 0.45 0.80
other than lung
Controls with COPD 7 14 15 36 1.09 0.58
COPD, chronic obstructive pulmonary disease.
aDNArestrictionfragmentlengthpolymorphism(RFLP)patterndeterminedbySouthernblotorpolymerasechainreaction-RFLPanalysis, L 10
kb and S = 6.6 kb EcoRI fragments ofthe L-myc proto-oncogene.
bDegrees offreedom = 2.
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FIGURE 3. Strategyforpolymerase chainreaction(PCR)-restriction enzymeanalysisofhumangenomic DNAfortheAccIIpolymorphisminexon4of
p53. High molecular-weight DNAisolated fromwhiteblood cells ofsubjects accrued in a case-control study oflung cancerwas amplified for 35 cycles
using a standard protocol (25). The results ofAccII digestion are either a single fragment of 360 bp for individuals who are homozygous AccII
restriction-site absent (CCC or proline genotype), a pair offragments of274 bp and 86 bp for individuals who are homozygousAccII restriction-site
present (CGC orarginine genotype), orthreefragmentsfortheheterozygote (360bp,274bp, and86bp).Theundigested controlis37bplongerthanall
ofthe digested materials because ofthe presence oftheAccII site introduced by the 5' primer. Fragments generated with the 3'B primer are 40 bp
shorter at the 3' end.
proline variant of p53 does not appear to predict lung
cancerrisk. Eachofthesepotentiallyusefulbiomarkers of
lung cancer risk displayed a strong association with race:
that is, allelotypic distributions were dependent on the
racial origin of the study subjects (African Americans
compared to Caucasians). These data indicate that the
H-ras-1, L-myc, and p53 polymorphisms should be exam-
ined in more detail with regard to their potential as
indicators ofindividual cancerrisk, as should theunderly-
ingmechanisms thatmayberesponsible forriskofcancer
when certain genotypes are inherited. Furthermore, the
data indicate the importance of controlling for race as a
confounding factor in epidemiological studies.
Theunderlyingmechanisticbasisforthecontributionof
the inheritance of H-ras-1 rare alleles to risk of lung
cancer is not known; however, the variable tandem repeat
(VTR) region may be involved in somatic-recombinational
events,implyingthatcertaintypes ofVTR aremorestable
than others (19). This hypothesis maybe extended toVTR
regions other than that at the H-ras-1 gene locus. Alter-
nately, VTR regions may have gene enhancer activity
(20,21), therefore, it follows that certain variants may be
more activethanothers. Notwithstandingthe absence ofa
clearmechanisticbasisfortheobservationsreportedhere,
they are supported by the results of a number of other
studies (22-24),and,althoughthedataintheliterature are
conflicting (25), not all studies of lung cancer have con-
trolled fortheconfoundingfactorsoftobacco smokingand
racial background ofthe study subjects.
It was reported previously, by Kawashima et al. (26),
thattheEcoRI restriction site-present allele atthe L-myc
gene locus (S allele) was an indicator of lymph node
metastasis (poor prognosis) in Japanese lung cancer
patients. This hypothesis and the hypothesis that inheri-
tance ofS alleles isindicative oflung cancerriskhave now
beentestedintwoindependentstudies (10,17).Contraryto
theresultsofthestudyinaJapanesepopulation,neitherof
the two subsequent studies found associations in Cauca-
sian populations.
L-myc genotyping has been conducted in a variety of
cancer groups, mainly ofJapanese origin. An association
was found in the case of lung (surgical diagnosis) (26),
renal (18), gastric (27), and bone cancers (28) between
increased frequency ofthe S allele and advanced disease
(metastasis); however, no association was found for lung
[clinical diagnosis (26)], colorectal (29), or breast cancers
(30). The reasons for these apparently contradictory
results are unclear, but a genetic difference related to
ethnicitycould existbetweenrespectivelungcancerpopu-
lations, even though the allelic frequencies in American
Caucasians and Japanese controls do not differ signifi-
cantly (L:S, 0.562:0.438 versus 0.485:0.515). Future stud-
ieswhich examine this question should control strictlyfor
variationduetoraceandbedesignedtoeliminatepotential
bias. Given that allelic frequency varies with ethnicity
(L:S, 0.277:0.763 and 0.562:0.438 for African Americans
and Caucasians, respectively), if one ethnic group consis-
tently seeks medical attention at a later stage, or is com-
m
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posed ofanunusual number ofprevalent (versus incident)
cases, or is associated with a particular histology or
exposure, bias could result. In the present study, the
prognostic associations considered were similarin Cauca-
sians and African Americans.
Forp53, the proline variant ofthe polymorphism in the
codingregionismorefrequentinAfricanAmericans than
in Caucasians. No evidence was found, however, for an
association betweenthepresence orabsence oftheproline
variant and lung cancer risk.
Tobacco smoke is the major etiological factor in lung
cancer, however, not all individuals who smoke cigarettes
develop lung cancer, and some individuals with little or no
exposure develop lung cancer (31). These observations
suggest that other factors maybe important in the deter-
mination oflung cancerrisk. Using acase-control design,
wehaveevaluatedthreepolymorphicgeneticloci(H-ras-1,
L-myc, and p53) as potential biomarkers of lung cancer
risk. Racial variation in allelic distribution was apparent
for each of these polymorphisms, which suggests that
controlling for racial variation as a confounding factor in
epidemiological studies is an important consideration in
study design.
This manuscript was presented at the Conference on Biomonitoring
and SusceptibilityMarkers in Human Cancer: Applications in Molecular
Epidemiology and Risk Assessment that was held in Kailua-Kona,
Hawaii, 26 October-1 November 1991.
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